No Data
Shanghai Henlius Advances Phase 3 Trial of HLX22 in Japan
HENLIUS (02696.HK): The international multicenter phase 3 clinical study comparing HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) combined with trastuzumab and chemotherapy (XELOX) versus trastuzumab and chemotherapy (XELOX) either
On March 26, Gelonghui reported that HENLIUS (02696.HK) announced the recent completion of the administration to the first patient in Japan for an international multicenter phase 3 clinical trial comparing HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) in combination with trastuzumab and chemotherapy (XELOX) against trastuzumab and chemotherapy (XELOX) with or without pembrolizumab as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal junction and gastric cancer. This phase 3 clinical trial is also being conducted in mainland China.
Shanghai Henlius Biotech Gets Approval for Kidney Treatment Clinical Trial in China; Shares Rise 3%
Hong Kong stocks movement | HENLIUS (02696) rose nearly 6% in the morning, with a year-on-year net profit increase of over 50%. HLX79 injection approved for clinical use.
HENLIUS (02696) rose nearly 6% in the early session, as of the time of writing, it had increased by 5.36%, priced at 30.45 Hong Kong dollars, with a transaction volume of 11.7617 million Hong Kong dollars.
Announcement Highlights | Kuaishou's adjusted Net income in Q4 increased by 7.8% year-on-year, and the total revenue of Keliang AI exceeded 0.1 billion yuan; CHINA TELECOM will earn 33 billion yuan in net income in 2024.
CHINA TELECOM's net income in 2024 is 33 billion yuan; WULING MOTORS' net income attributable to shareholders is expected to increase by over 115% in 2024; Kuaishou's net income in 2024 is 15.335 billion yuan, an increase of 139.76% year-on-year.
Shanghai Henlius Biotech Advances in Autoimmune Treatment With Phase 2 Trial Approval
